| Project/Area Number |
18K19485
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 50:Oncology and related fields
|
|---|
| Research Institution | Japanese Foundation for Cancer Research |
|---|
Principal Investigator |
Kiyotani Kazuma 公益財団法人がん研究会, がんプレシジョン医療研究センター 免疫ゲノム医療開発プロジェクト, 主任研究員 (30433642)
|
|---|
| Project Period (FY) |
2018-06-29 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2019: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2018: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Keywords | 翻訳後修飾 / ネオセルフ抗原 / T細胞受容体 / ネオアンチゲン / LC-MS/MS |
|---|
| Outline of Final Research Achievements |
In this study, we investigated whether neo-self peptides derived from mutilated proteins encoded by oncogenes. We generated all possible peptides with methylated amino acid using bioinformatic approach and predicted their binding affinities to HLA class I molecules. Through the analysis, we obtained two possible candidates of methylated proteins which can be presented on HLA molecules. From HLA-matched healthy donor’s blood sample, we successfully induced methylated peptide-specific T cells for one of them. We also identified the TCRalpha/beta sequences of the T cells, and generated TCR-engineered T cells.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、翻訳後修飾（特にメチル化）を受けたタンパク質由来の抗原がT細胞の標的となりうるかを検証した。これまでに翻訳後修飾を受けたペプチドがHLA上に提示されていることは報告されていた。本研究では、実際に初めて翻訳後修飾を受けたペプチドを特異的に認識するT細胞の同定に成功した。本研究の成果は、学術的にも、また新たながん免疫療法の標的としても大変重要な成果である。
|
